|Bid||309.61 x 900|
|Ask||309.70 x 900|
|Day's range||307.17 - 312.45|
|52-week range||263.30 - 380.76|
|Beta (3Y monthly)||1.31|
|PE ratio (TTM)||49.13|
|Earnings date||24 Oct 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||329.25|
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina, Inc. (ILMN) today announced that it will issue results for third quarter 2019 following the close of market on Thursday, October 24, 2019. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, October 24, 2019.
Illumina, Inc. (ILMN) and QIAGEN N.V. (QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management. The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina’s MiSeq™ Dx and NextSeq™ 550Dx Systems. The agreement also includes rights for expansion of the partnership on future Illumina diagnostic (Dx) systems.
The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Illumina, Inc. (ILMN) and the Broad Institute of MIT and Harvard today announced they have entered into a collaboration for the co-development of secondary genomic analysis algorithms and software. Top data scientists from both institutions will collaborate to bring together the industry-leading open-source GATK algorithms with the speed and enhanced accuracy of Illumina’s DRAGEN™ (Dynamic Read Analysis for GENomics) Bio-IT Platform for commonly used methods, including small variant (SNV) and large variant (CNV/SV) detection.
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
Illumina, Inc. (ILMN) today announced the appointment of Joydeep Goswami as Senior Vice President of Corporate Development and Strategic Planning. Mr. Goswami will be responsible for driving planning, strategic partnerships and acquisitions, and will report to President and Chief Executive Officer, Francis deSouza. With more than 20 years of global experience, Mr. Goswami has a strong track record of developing strategy and leading new product development, partnerships, licensing, and mergers and acquisitions.
Illumina, Inc. (“Illumina”) (ILMN) has been notified of an unsolicited “mini-tender offer” by TRC Capital Corporation (“TRC”) to purchase up to 500,000 shares of Illumina common stock at a price of $268.80 per share in cash. Illumina is not affiliated or associated in any way with TRC, its offer or the offer documentation. Illumina recommends that stockholders not tender their shares in response to TRC's unsolicited offer because, among other things, it deprives stockholders who tender their Illumina shares of the potential opportunity to realize greater long-term value in their investment.
The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.
Examining Illumina, Inc.'s (NASDAQ:ILMN) past track record of performance is a useful exercise for investors. It...
Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.